10 important recent drug approvals, retained until verified newer approvals replace them.
Approved use: PET imaging to help differentiate recurrent/progressive glioma from treatment-related change.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Spinal muscular atrophy in patients age 2 years and older receiving an SMN2-targeted treatment.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: ESR1-mutated HR-positive/HER2-negative locally advanced or metastatic breast cancer in the FDA-specified setting.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Alexander disease in pediatric and adult patients.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Erythrocytosis in adults with polycythemia vera.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Dermatomyositis in adults.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Metastatic pancreatic cancer.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Reduction of new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Combination treatment for adults with multiple myeloma after at least one prior line of therapy, as specified by FDA.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.
Approved use: Brain PET imaging in adults with cognitive impairment being evaluated for Alzheimer disease to identify tau neurofibrillary tangle pathology.
Clinical note: Recent novel FDA approval with potential clinical relevance; verify the current prescribing information before use.